Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
Explore this paper's citation graph
Summary
The aim of the present study was to evaluate the efficacy and safety of lurasidone for the treatment of Chinese schizophrenic patients.
- Type
- article
- Published
- 2019-12-10
- Cited by
- 15
- References
- 39
- Access
- Open access
- OpenAlex
- https://openalex.org/W2996122858
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:209317004
Keywords
Lurasidone, Risperidone, Akathisia, Positive and Negative Syndrome Scale, Extrapyramidal symptoms
References
- Assessing Depression in Schizophrenia: The Calgary Depression Scale
- Handbook of adult psychopathology in Asians : theory, diagnosis, and treatment
- Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second‐generation antipsychotic
- Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
- Occupational functioning, symptoms and neurocognition in patients with psychotic disorders: investigating subgroups based on social security status
- Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
- Risperidone versus placebo for schizophrenia.
- The lifetime risk of suicide in schizophrenia: a reexamination.
- Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
- Pattern of Mortality in a Sample of Maryland Residents with Severe Mental Illness
- Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial
- Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
- Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety
- A Rating Scale for Drug-Induced Akathisia
- Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance
- Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
- Factors That Influence the Prescription of Antipsychotics for Patients with Schizophrenia in China
- Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
- Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective
Cited by
- A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
- The effects of systematic psychological nursing on the sleep quality of schizophrenic patients with sleep disorders.
- Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
- The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework.
- Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
- The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
- Brexpiprazole-Induced Hyperprolactinemia in Patient With Pituitary Gland Tumor.
- Second‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database
- Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study
- Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients
- Lurasidone in monotherapy in a patient with a diagnosis paranoid schizophrenia - monitoring the effect on psychoptatology and somatic health
- Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance
- New molecular entities and structure–activity relationships of drugs designed by the natural product derivatization method from 2010 to 2018
- World Journal of Psychiatry
- Influence of DRD2, ANKK1 and 5-HTR2A Gene Polymorphisms on Extrapyramidal Symptoms Induced by Risperidone
Related papers
- Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
- A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
- A new atypical antipsychotic drug:lurasidone
- The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
- Relationship between the plasma concentration of paliperidone and the clinical and drug‐induced extrapyramidal symptoms in elderly patients with schizophrenia
- Risperidone in the Treatment of Elderly Patients With Psychotic Disorders
- Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.
- Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
- Risperidone in the treatment of elderly patients with psychotic disorders.
- Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis)